- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03871231
Unpinning Termination Therapy for VT/VF
An International Clinical Feasibility Study to Evaluate the Safety and Performance of Low-Energy Unpinning Termination Therapy in Patients With VT/VF
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A prospective single-arm feasibility study involving acute testing of UPT electrotherapy in subjects with VT/VF during clinically indicated ventricular tachycardia catheter ablation procedure or indicated implantable cardioverter defibrillator implant, upgrade, or replacement or new CRT-D implant or upgrade to CRT-D.
The study involves up to two roll in subjects at each participating site followed by an UPT evaluation and refinement segment in which remaining subjects are enrolled until arrhythmia terminations from UPT delivery are reliably achieved. A prospective evaluation segment will be performed to compare UPT against SBS and ATP if sufficient subjects remain once reliable terminations from UPT are achieved.
Subjects will be evaluated at the visits for the Clinically-Indicated Procedure per standard of care. A single follow-up at up to 30 days post-procedure is required to assess subjects for adverse events.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Queensland
-
Chermside, Queensland, Australia, 4032
- The Prince Charles Hospital
-
Southport, Queensland, Australia, 4215
- Gold Coast
-
-
South Australia
-
Norwood, South Australia, Australia, 5067
- Royal Adelaide Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Medical
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Life expectancy of 1 year or greater
- Male or female between 18 and 75 years of age
- Willing and able to comply with the study protocol, provide a written informed consent
- Indication for an endocardial VT catheter ablation for sustained, life-threatening monomorphic VT OR an indication for VF and ICD implant (de novo implant, replacement or upgrade) OR CRT-D (de novo implant, upgrade from ICD) with transvenous leads for the risk of or presence of VT and/or VF.
- Etiology of arrhythmia, or risk of arrhythmia being ischemic dilated cardiomyopathy or non-ischemic idiopathic dilated cardiomyopathy both with LVEF ≤ 35% and meeting local standard of care
- Medically stable at time of consent to undergo DFT testing performed under general anesthesia or conscious sedation as determined by the investigator
Exclusion Criteria:
The subject must not meet any of the following exclusion criteria:
- Medically unstable at time of study and unsafe to undergo DFT testing under general anesthesia or conscious sedation as determined by the investigator
- Hemodynamic instability as determined by the investigator
- AF or atrial flutter for ≥ 48 hours or unknown duration, and no anticoagulation for preceding 3 weeks and no preoperative transesophageal echocardiographic confirmation of the absence of RA and LA thrombus
- AF or atrial flutter for <48 hours and no Preoperative transesophageal echocardiographic confirmation of the absence of RA and LA thrombus
- Presence of intracardiac thrombus
- Inability to pass catheters to heart due to vascular limitations
- Cardiovascular anatomical defects that would complicate placement of the lead or catheter required by the protocol, including congenital heart disease and cardiac vein anomalies as determined by the investigator
- Pregnancy confirmed by test within 7 days of procedure
- Pacemaker dependent
- The presence of a normally functioning left ventricular lead which is not planned for revision
- Presence of ventricular assist device, including Intra-aortic balloon pump
- Subjects requiring the use of I.V. inotropes and/or vasopressors for hemodynamic support in the 14 days prior to the study
- Prior VT catheter ablation with associated serious complication, such as hemodynamic compromise despite pressor agents, stroke, cardiac perforation, AC fistula, pneumothorax, sepsis
- Incessant VT/VF or VT/VF storm
- LVEF < 20%
- New York Heart Association (NYHA) Class IV heart failure
- Planned epicardial VT ablation on the same day as the research study
- History of hyper-coagulable state that could increase risk of thromboembolic events
- History of hemodynamic compromise due to valvular heart disease requiring IV inotropes or other circulatory support.
- Unstable coronary artery disease as determined by the investigator
- Severe proximal three-vessel or left main coronary artery disease, without revascularization as determined by the investigators
- History of embolic stroke, Transient Ischemic Attack or other thromboembolic event in the past 6 months
- History of Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Congenital Heart Anomaly, Cardiac Amyloidosis, Genetic Cardiac Channelopathy or Cardiac Sarcoidosis.
- Cardiovascular surgery or intervention within 1 month prior to enrollment or planned for up to 1 month after enrollment (other than the planned treatment procedure)
- Morbid obesity: BMI>39 kg/m2
- Cognitive or mental health status that would interfere with study participation and proper informed consent
- Presence of mechanical tricuspid valve
- Active Endocarditis
- Ventricular arrhythmia etiology sarcoidosis
- Valvular ventricular tachycardia
- Previously implanted lead is under recall by manufacturer or evidence of lead failure as determined by the investigator
- End Stage Renal Disease on hemodialysis or peritoneal dialysis, or estimated glomerular filtration rate (eGFR) <15 ml/min
- Right atrial or right ventricular lead implanted within 12 months prior to screening
- Any other medical condition which may affect the outcome of this study or safety of the subject as determined by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DEVICE_FEASIBILITY
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Unpinning Termination Therapy Arm
Subjects will have VT/VF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia
|
The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy.
The CESS is a custom designed and built research device.
It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of UPT therapy
Time Frame: Study procedure and 30 day post procedure
|
Adverse events
|
Study procedure and 30 day post procedure
|
Safety of UPT therapy
Time Frame: 30 day post procedure
|
Adverse events
|
30 day post procedure
|
Parameters at which UPT terminates VT and VF
Time Frame: Study procedure
|
Voltage
|
Study procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Voltage at which UPT and endocardial single biphasic shock terminate VT/VF
Time Frame: Study procedure
|
Voltage
|
Study procedure
|
Voltage at which UPT and ATP terminate VT
Time Frame: Study procedure
|
Voltage
|
Study procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Harris Haqqani, MD, The Prince Charles Hospital
Publications and helpful links
General Publications
- Janardhan AH, Gutbrod SR, Li W, Lang D, Schuessler RB, Efimov IR. Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock. J Am Coll Cardiol. 2014 Jan 7-14;63(1):40-8. doi: 10.1016/j.jacc.2013.07.098. Epub 2013 Sep 26.
- Li W, Janardhan AH, Fedorov VV, Sha Q, Schuessler RB, Efimov IR. Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):917-25. doi: 10.1161/CIRCEP.111.965830. Epub 2011 Oct 6.
- Efimov I, Ripplinger CM. Virtual electrode hypothesis of defibrillation. Heart Rhythm. 2006 Sep;3(9):1100-2. doi: 10.1016/j.hrthm.2006.03.005. Epub 2006 Mar 10. No abstract available.
- Ambrosi CM, Ripplinger CM, Efimov IR, Fedorov VV. Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy. Heart Rhythm. 2011 Jan;8(1):101-8. doi: 10.1016/j.hrthm.2010.10.018. Epub 2010 Oct 19.
- Janardhan AH, Li W, Fedorov VV, Yeung M, Wallendorf MJ, Schuessler RB, Efimov IR. A novel low-energy electrotherapy that terminates ventricular tachycardia with lower energy than a biphasic shock when antitachycardia pacing fails. J Am Coll Cardiol. 2012 Dec 11;60(23):2393-8. doi: 10.1016/j.jacc.2012.08.1001. Epub 2012 Nov 7.
- Ripplinger CM, Krinsky VI, Nikolski VP, Efimov IR. Mechanisms of unpinning and termination of ventricular tachycardia. Am J Physiol Heart Circ Physiol. 2006 Jul;291(1):H184-92. doi: 10.1152/ajpheart.01300.2005. Epub 2006 Feb 24.
- Li W, Ripplinger CM, Lou Q, Efimov IR. Multiple monophasic shocks improve electrotherapy of ventricular tachycardia in a rabbit model of chronic infarction. Heart Rhythm. 2009 Jul;6(7):1020-7. doi: 10.1016/j.hrthm.2009.03.015. Epub 2009 Mar 11.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventricular Fibrillation
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Enrolling by invitationShort-coupled Idiopathic Ventricular FibrillationNetherlands
-
Guidant CorporationBoston Scientific CorporationCompletedHeart Failure | Ventricular Tachycardia, Ventricular FibrillationIsrael, Denmark
-
Boston Scientific CorporationCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular TachycardiaUnited States, Netherlands
-
Biosense Webster, Inc.CompletedVentricular Tachycardia | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Scar-related Atrial Tachycardia | Premature Ventricular ComplexCroatia, Italy, Israel
-
Biosense Webster, Inc.CompletedVentricular Tachycardia | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Scar-related Atrial Tachycardia | Premature Ventricular ComplexCroatia, Belgium, Italy
-
Mayo ClinicMedtronicCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular Tachycardia | Supraventricular TachycardiaUnited States, Israel
-
Institute for Clinical and Experimental MedicineRecruitingAtrial Fibrillation | Acute Heart Failure | Left Ventricular Dysfunction | Atrial Fibrillation RapidCzechia
-
University of Turin, ItalyUniversity of Padova; Centro Cardiologico Monzino; Policlinico Casilino ASL RMB; Humanitas Research Hospital IRCCS, Rozzano-MilanUnknownPersistent Atrial Fibrillation | Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction
-
Abbott Medical DevicesCompletedVentricular Tachycardia | Persistent Atrial FibrillationCanada, South Africa, Denmark, Australia, Italy, Austria, France, Germany, Netherlands, Portugal, Spain
-
Ottawa Heart Institute Research CorporationNot yet recruitingVentricular Fibrillation | Ventricular Tachycardia | Ventricular Arrhythmias | Recurrent Ventricular Tachycardia
Clinical Trials on Unpinning Termination Therapy
-
Cardialen, Inc.Washington University School of Medicine; National Heart, Lung, and Blood Institute...Terminated
-
Cardialen, Inc.Iqvia Pty Ltd; AvaniaTerminatedAtrial Fibrillation | Atrial Fibrillation, Persistent | Atrial Fibrillation, ParoxysmalAustralia
-
Kanuni Sultan Suleyman Training and Research HospitalCompleted
-
National Taiwan University HospitalSingapore Clinical Research InstituteRecruitingOut-Of-Hospital Cardiac ArrestTaiwan
-
National Research Institute for Family Planning...UnknownReproductive HealthChina
-
University of Southern DenmarkNot yet recruitingOut-Of-Hospital Cardiac Arrest
-
Shanghai Chest HospitalNot yet recruitingAtrial Fibrillation | Cathter Ablation | EndpointChina
-
North-Western State Medical University named after...CompletedEdentulous | Teeth Replacement | Bounded Edentulous Space
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Variceal BleedingIndia
-
University of California, San FranciscoCenter for Research on Environment Health and Population Activities (CREHPA)Active, not recruiting